From: A systematic review of biomarkers for disease progression in Parkinson’s disease
All studies (n=183) | Longitudinal studies (n=20) | Cross-sectional studies (n=163) | P value | ||||
---|---|---|---|---|---|---|---|
Baseline demographics | |||||||
Median number of patients | 32 | (21 to 53) | 31 | (16 to 36) | 34 | (22 to 55) | 0.058 |
Mean age (years) | 63.5 | (5.6) | 63.7 | (6.7) | 63.4 | (5.5) | 0.771 |
Mean percentage male | 58.7 | (13.9) | 67.3 | (15.6) | 57.7 | (13.3) | 0.002 |
Median disease duration (years) | 5.7 | (3.6 to 7.4) | 3.2 | (1.7 to 5.9) | 5.9 | (4.1 to 7.6) | 0.005 |
Median percentage treated | 76.8 | (51.2 to 88.8) | 40.6 | (0.0 to 71.1) | 78.5 | (56.7 to 90.2) | 0.005 |
Baseline disease severity | |||||||
Median total UPDRS | 33.3 | (29.4 to 40.6) | 31.8 | (30.1 to 38.7) | 33.3 | (29.4 to 40.6) | 0.790 |
Median UPDRS (II) | 14.7 | (11.6 to 16.3) | 9.1 | (Insufficient data for IQR) | 14.8 | (11.9 to 16.6) | 0.023 |
Median UPDRS (III) | 21.0 | (16.6 to 26.3) | 22.4 | (16.3 to 28.5) | 20.9 | (16.8 to 25.8) | 0.864 |
Median Hoehn & Yahr | 2.5 | (2.0 to 2.8) | 1.8 | (1.6 to 2.0) | 2.5 | (2.1 to 2.9) | <0.001 |
Median MMSE | 25.8 | (23.0 to 28.1) | 25.5 | (22.3 to 28.3) | 25.8 | (23.0 to 28.1) | 1.000 |